Efficacy and safety of omalizumab use in chronic idiopathic urticari

Chronic idiopathic urticaria is an important medical and social problem, which is more common in children than in adults. According to statistics, CIU affects about 0.5-5% of the population, and women suffer from this disease twice as often as men. At present, one of the important problems of CIU therapy is the difficulty of controlling the course of the disease and the development of tolerance to treatment with first-line drugs of baseline CIU therapy. According to the clinical recommendations of the Russian Federation, the drug of the second stage of therapy is omalizumab. Omalizumab is a recombinant humanized monoclonal antibody that selectively binds to free IgE and inhibits the interaction of IgE with the FcεRI receptor on mast cells and basophils. The use of this drug is of practical interest due to the specific point of application, resulting in greater treatment efficacy and less probability of adverse reactions. Currently, there are a large number of studies assessing the efficacy and safety of omalizumab in medical practice, but due to the limited number of patients in the cohort of subjects, the profile of adverse reactions remains incomplete. We analyzed 9 studies on the efficacy and safety of omalizumab in adults and children with chronic idiopathic urticaria.